drugset / Trial / NCT06509958

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

NCT06509958

Phase 2 Terminated 15 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management in total knee arthroplasty compared with ropivacaine.

Timeline

Start
2024-08-20
Primary completion
2024-10-10
Completion
2024-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HR18034 Unknown Other
Comparator Ropivacaine Other / unclassified

Indications

No indication recorded.